Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Mar 28 02:19PM ET
1.31
Dollar change
0.00
Percentage change
0.00
%
Index- P/E- EPS (ttm)-1.86 Insider Own33.54% Shs Outstand54.94M Perf Week-4.38%
Market Cap72.84M Forward P/E- EPS next Y-0.98 Insider Trans-0.19% Shs Float36.95M Perf Month-24.28%
Income-102.06M PEG- EPS next Q-0.36 Inst Own20.93% Short Float3.28% Perf Quarter39.01%
Sales0.00M P/S- EPS this Y35.97% Inst Trans-6.59% Short Ratio2.82 Perf Half Y97.17%
Book/sh2.03 P/B0.65 EPS next Y18.10% ROA-51.80% Short Interest1.21M Perf Year35.05%
Cash/sh2.06 P/C0.64 EPS next 5Y- ROE-65.29% 52W Range0.58 - 1.79 Perf YTD29.70%
Dividend Est.- P/FCF- EPS past 5Y-46.23% ROI-76.05% 52W High-26.82% Beta1.29
Dividend TTM- Quick Ratio7.22 Sales past 5Y0.00% Gross Margin- 52W Low127.79% ATR (14)0.16
Dividend Ex-Date- Current Ratio7.22 EPS Y/Y TTM25.46% Oper. Margin0.00% RSI (14)46.86 Volatility11.79% 13.66%
Employees58 Debt/Eq0.24 Sales Y/Y TTM- Profit Margin- Recom1.00 Target Price7.00
Option/ShortYes / Yes LT Debt/Eq0.21 EPS Q/Q38.47% Payout- Rel Volume0.42 Prev Close1.31
Sales Surprise- EPS Surprise22.28% Sales Q/Q- EarningsMar 04 BMO Avg Volume429.80K Price1.31
SMA20-10.85% SMA505.54% SMA20045.72% Trades Volume135,906 Change0.00%
Date Action Analyst Rating Change Price Target Change
Mar-08-22Downgrade JP Morgan Overweight → Neutral
Jan-19-22Downgrade Goldman Buy → Neutral $29 → $6
Jul-01-21Initiated Raymond James Outperform $29
Jun-15-21Initiated BTIG Research Buy $25
Mar-04-21Upgrade Goldman Neutral → Buy $28 → $30
Feb-04-21Initiated Guggenheim Buy $25
Jan-25-21Initiated Wedbush Outperform $26
Jan-04-21Upgrade JP Morgan Neutral → Overweight $25 → $35
Dec-11-20Initiated Citigroup Neutral $28
Aug-14-20Downgrade JP Morgan Overweight → Neutral $25
Mar-07-24 12:00PM
Mar-06-24 01:52PM
Mar-05-24 07:00AM
Mar-04-24 07:00AM
Feb-27-24 07:00AM
07:09PM Loading…
Feb-01-24 07:09PM
Jan-31-24 07:30AM
Dec-25-23 10:14PM
Dec-20-23 07:00AM
Nov-17-23 04:30PM
Nov-13-23 07:00AM
Oct-30-23 07:00AM
Oct-20-23 04:30PM
Sep-25-23 07:00AM
Aug-11-23 10:04AM
07:15AM Loading…
Aug-07-23 07:15AM
07:00AM
Aug-01-23 07:00AM
Jul-31-23 07:00AM
Jul-24-23 12:37PM
Jul-06-23 11:17AM
Jun-05-23 07:00AM
May-11-23 07:00AM
May-04-23 07:00AM
Apr-21-23 04:01PM
Apr-17-23 07:00AM
Mar-29-23 09:02AM
Mar-27-23 07:00AM
Mar-08-23 07:14AM
Mar-07-23 12:42AM
07:00AM Loading…
Mar-06-23 07:00AM
Mar-01-23 07:00AM
Feb-28-23 07:00AM
Feb-27-23 07:00AM
Feb-24-23 07:00AM
Feb-20-23 05:59PM
Feb-15-23 07:00AM
Jan-20-23 04:01PM
Jan-07-23 07:39AM
Dec-14-22 12:13PM
07:00AM
Nov-21-22 05:24AM
Nov-10-22 07:00AM
Nov-08-22 07:00AM
Nov-03-22 07:30AM
Oct-14-22 04:01PM
Oct-11-22 12:25PM
Oct-10-22 07:00AM
Sep-26-22 07:00AM
Aug-19-22 04:01PM
Aug-11-22 07:00AM
Aug-05-22 07:00AM
Aug-04-22 07:00AM
Jul-28-22 07:30AM
Jul-21-22 04:01PM
Jul-12-22 08:19AM
Jul-06-22 07:00AM
Jun-09-22 07:30AM
Jun-08-22 07:30AM
Jun-01-22 10:19AM
07:30AM
May-20-22 04:01PM
May-18-22 07:00AM
May-16-22 07:00AM
May-09-22 07:00AM
May-04-22 10:55AM
May-03-22 02:13PM
May-02-22 04:01PM
Apr-22-22 04:01PM
Mar-29-22 07:00AM
Mar-28-22 07:00AM
Mar-15-22 11:22AM
11:12AM
07:00AM
Mar-10-22 07:00AM
Mar-03-22 07:00AM
Mar-01-22 07:00AM
Feb-24-22 07:00AM
Feb-11-22 11:00AM
Feb-01-22 12:49PM
Jan-31-22 07:00AM
Jan-10-22 07:00AM
Jan-03-22 07:00AM
Dec-17-21 07:00AM
Dec-08-21 02:35PM
07:00AM
Nov-30-21 11:08AM
Nov-19-21 04:00PM
Nov-12-21 05:51AM
Nov-09-21 07:00AM
Nov-04-21 07:00AM
Nov-01-21 03:05PM
Oct-28-21 07:00AM
Sep-29-21 04:42PM
Sep-27-21 07:00AM
Sep-17-21 04:01PM
Sep-07-21 07:00AM
Sep-02-21 07:00AM
Aug-05-21 07:00AM
Aug-04-21 09:00PM
Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Forman Mark SCHIEF MEDICAL OFFICERFeb 13 '24Sale0.971,6381,58948,631Feb 13 07:34 PM
Borthwick KathleenSVP, INTERIM CFOFeb 13 '24Sale0.971,4701,42628,466Feb 13 07:36 PM
Forman Mark SChief Medical OfficerJan 02 '24Sale0.9115,81314,39045,269Jan 03 04:21 PM
Cale Edgar B.GC & Corporate SecretaryJan 02 '24Sale0.9115,81314,39045,995Jan 03 04:19 PM
King SimonaChief Financial OfficerJul 28 '23Option Exercise0.0031,250035,447Aug 01 04:36 PM
King SimonaChief Financial OfficerJul 28 '23Sale0.8811,45310,07923,994Aug 01 04:36 PM
ORBIMED ADVISORS LLC10% OwnerJun 28 '23Buy0.84575,195483,1648,034,000Jun 29 04:42 PM
ORBIMED ADVISORS LLC10% OwnerJun 27 '23Buy0.84617,382518,6017,458,805Jun 29 04:42 PM
Fotopoulos AlexandrosChief Technical OfficerJun 16 '23Sale0.934,0523,77828,693Jun 20 04:10 PM
Fotopoulos AlexandrosChief Technical OfficerJun 15 '23Option Exercise0.0012,500032,745Jun 20 04:10 PM
King SimonaChief Financial OfficerApr 18 '23Option Exercise0.006,25006,250Apr 20 04:28 PM
King SimonaChief Financial OfficerApr 18 '23Sale1.052,0532,1562,053Apr 20 04:28 PM